Hiroshi Tanabe

Dr. Hiroshi Tanabe


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SHSou Hirose
Sou Hirose
HTHiroshi Tanabe
Hiroshi Tanabe
YNYouko Nagayoshi
Youko Nagayoshi
YHYukihiro Hirata
Yukihiro Hirata
CNChikage Narui
Chikage Narui
AOAikou Okamoto
Aikou Okamoto
Hirose S, et al. J Gynecol Oncol. 2017 Dec;29:e37. https://doi.org/10.3802/jgo.2018.29.e37

1 January 2018 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HTHirokuni Takano
Hirokuni Takano
KNKeiko Nakajima
Keiko Nakajima
YNYoko Nagayoshi
Yoko Nagayoshi
HKHiromi Komazaki
Hiromi Komazaki
JSJiro Suzuki
Jiro Suzuki
AOAikou Okamoto
Aikou Okamoto
Takano H, et al. J Gynecol Oncol. 2017 Dec;29:e67. https://doi.org/10.3802/jgo.2018.29.e67

1 October 2008 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Shin NishioShin Nishio
Shin Nishio
NKNoriyuki Katsumata
Noriyuki Katsumata
KMKoji Matsumoto
Koji Matsumoto
HTHiroshi Tanabe
Hiroshi Tanabe
KYKan Yonemori
Kan Yonemori
YFYasuhiro Fujiwara
Yasuhiro Fujiwara

31 July 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTadahiro Shoji
Tadahiro Shoji
SKShinichi Komiyama
Shinichi Komiyama
JKJunzo Kigawa
Junzo Kigawa
HTHiroshi Tanabe
Hiroshi Tanabe
KKKazuyoshi Kato
Kazuyoshi Kato
TSToru Sugiyama
Toru Sugiyama
We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer. We hypothesize that patients treated with a combination of single-agent chemotherapy and bevacizumab will show improved progression-free survival (PFS) compared with those treated with single-agent chemotherapy alone, in the setting beyond disease progression following prior bevacizumab treatment. A total of 106 patients who have recurrence or progression of ovarian cancer, while receiving chemotherapy or within 6 months after the final dose of platinum, after completing at least three cycles of bevacizumab plus platinum chemotherapy will be randomized in a 1:1 ratio to treatment with single-agent chemotherapy or single-agent chemotherapy combined with bevacizumab. For chemotherapy, one of the following four drugs will be chosen by an investigator: pegylated liposomal doxorubicin, topotecan, paclitaxel, or gemcitabine. The primary endpoint is investigator-assessed PFS. The secondary endpoints are overall survival, objective response rate, number of paracentesis, and response rate by CA125. Safety will be evaluated by the incidence of adverse events. This study will assess the efficacy and safety of bevacizumab in combination with single-agent chemotherapy, which could be used continuously after disease progression following standard platinum-based chemotherapy with bevacizumab. UMIN000017247 (registered April 22, 2015).

27 September 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TSToshiyuki Seki
Toshiyuki Seki
HTHiroshi Tanabe
Hiroshi Tanabe
CNChie Nagata
Chie Nagata
JSJiro Suzuki
Jiro Suzuki
KSKayo Suzuki
Kayo Suzuki
AOAikou Okamoto
Aikou Okamoto
Patients with adeno/adenosquamous carcinoma may have a poorer prognosis than patients with squamous cell carcinoma. Radiotherapy and concurrent chemoradiotherapy are used as adjuvant therapies for cervical cancer, regardless of the histological subtype. The aim of this study was to investigate the prognostic outcome of adjuvant therapy for patients with adeno/adenosquamous carcinoma with pathological risk factors. The medical records of 135 patients with stage IB–IIB cervical cancer with squamous cell carcinoma or adeno/adenosquamous carcinoma who underwent primary surgery followed by adjuvant therapy were retrospectively reviewed. Patients with a pathologically confirmed bulky tumor (≥4 cm), nodal metastasis and/or parametrium invasion were included in the study. The median follow-up period was 48 (1–132) months. Of the 135 patients, 90 with squamous cell carcinoma and 23 with adeno/adenosquamous carcinoma were treated with adjuvant radiotherapy and concurrent chemoradiotherapy (SCC-RT/CCRT and AC-RT/CCRT groups), and 22 with adeno/adenosquamous carcinoma were treated with adjuvant systemic chemotherapy (AC-CT group). There were no significant differences in clinicopathological factors between the SCC-RT/CCRT and AC-RT/CCRT groups and between the AC-RT/CCRT and AC-CT groups. Progression-free survival was significantly shorter in the AC-RT/CCRT group compared to the SCC-RT/CCRT group ( P = 0.002). Adeno/adenosquamous carcinoma histology and multiple lymph node metastasis were independent prognostic factors for shorter progression-free survival in patients treated with adjuvant radiotherapy and concurrent chemoradiotherapy. Progression-free survival was also significantly shorter in the AC-RT/CCRT group compared to the AC-CT group ( P = 0.026). Adjuvant radiotherapy and concurrent chemoradiotherapy may be less effective for patients with adeno/adenosquamous carcinoma than for those with squamous cell carcinoma. Adjuvant systemic chemotherapy may be beneficial for adeno/adenosquamous carcinoma and further studies are warranted.

1 February 2008 in Oncology Reports
Verified
Journal Article
Open access
PDF file
Shin NishioShin Nishio
Shin Nishio
NKNoriyuki Katsumata
Noriyuki Katsumata
KMKoji Matsumoto
Koji Matsumoto
HTHiroshi Tanabe
Hiroshi Tanabe
KYKan Yonemori
Kan Yonemori
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
The aim of this study was to evaluate the clinicopathological prognostic factors in patients with stage IVb cervical carcinoma (CC). All patients with stage IVb CC included in the study were diagnosed from 1997 to 2006 at the National Cancer Center Hospital. We retrospectively examined clinicopathological parameters in these patients, including the efficacy of chemotherapy. Survival was evaluated using Kaplan-Meier curve analysis and log-rank test. The independent prognostic factors found to be predictive of survival in univariate and multivariate analysis were evaluated using a Cox's proportional hazard model. Thirty-six patients (median age 54 years) were diagnosed with stage IVb CC. The median progression-free survival and overall survival were 3.8 and 11.1 months, respectively. As initial treatment, 4 patients underwent hysterectomy, 13 received chemotherapy, 17 received radiotherapy, and the remaining 2 patients refused treatment. A total of 21 patients received chemotherapy, of which 13 were initial cases, 7 were persistent/recurrence cases, and 1 was a postoperative adjuvant case; 15 patients were never treated with chemotherapy. On univariate analysis, poor performance status (PS) and non-chemotherapy groups were considered poor prognostic factors, respectively. On multivariate analysis, poor PS (p=0.007; hazard ratio, 2.64) and non-chemotherapy (p=0.016; hazard ratio, 6.03) were independent prognostic factors of survival, respectively. Poor PS and non-chemotherapy groups were found to have poor prognosis in patients with stage IVb CC. Chemotherapy may improve the survival for stage IVb CC.